↓ Skip to main content

Dove Medical Press

Article Metrics

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments

Overview of attention for article published in Neuropsychiatric Disease and Treatment, October 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
35 Dimensions

Readers on

mendeley
69 Mendeley
Title
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
Published in
Neuropsychiatric Disease and Treatment, October 2013
DOI 10.2147/ndt.s36693
Pubmed ID
Authors

Spyridon Konitsiotis, Panagiotis Bargiotas

Abstract

Parkinson's disease therapy is still focused on the use of L-3,4-dihydroxyphenylalanine (levodopa or L-dopa) for the symptomatic treatment of the main clinical features of the disease, despite intensive pharmacological research in the last few decades. However, regardless of its effectiveness, the long-term use of levodopa causes, in combination with disease progression, the development of motor complications termed levodopa-induced dyskinesias (LIDs). LIDs are the result of profound modifications in the functional organization of the basal ganglia circuitry, possibly related to the chronic and pulsatile stimulation of striatal dopaminergic receptors by levodopa. Hence, for decades the key feature of a potentially effective agent against LIDs has been its ability to ensure more continuous dopaminergic stimulation in the brain. The growing knowledge regarding the pathophysiology of LIDs and the increasing evidence on involvement of nondopaminergic systems raises the possibility of more promising therapeutic approaches in the future. In the current review, we focus on novel therapies for LIDs in Parkinson's disease, based mainly on agents that interfere with glutamatergic, serotonergic, adenosine, adrenergic, and cholinergic neurotransmission that are currently in testing or clinical development.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 1%
Unknown 68 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 13 19%
Researcher 13 19%
Student > Master 11 16%
Student > Ph. D. Student 11 16%
Other 6 9%
Other 10 14%
Unknown 5 7%
Readers by discipline Count As %
Medicine and Dentistry 18 26%
Agricultural and Biological Sciences 16 23%
Neuroscience 14 20%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Nursing and Health Professions 2 3%
Other 8 12%
Unknown 8 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2013.
All research outputs
#9,126,815
of 14,535,828 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,525
of 2,442 outputs
Outputs of similar age
#100,171
of 184,768 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#42
of 54 outputs
Altmetric has tracked 14,535,828 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 184,768 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.